Article
IDH2 clonal hematopoiesis and IKAROS loss cooperate in a B-ALL subtype after lenalidomide therapy for multiple myeloma.
Blood - 13 Aug 2026
Horns Johanna M, Beder Thomas, Künstner Axel, Barz Malwine J, Bendig Sonja, Bozzetti Cecilia, Chitadze Guranda, Darzentas Nikos, Iben Katharina, Kotrova Michaela, Martín-Subero José I, Mondal Mayukh, Neumann Martin, Pérez Raúl F, Ströh Aeint-Steffen, Weßels Wiebke, Lenk Lennart, Velten Lars, Böll Boris, Braitsch Krischan, Bücklein Veit, Duell Johannes, Faul Christoph, Fiedler Walter, Hanoun Maher, Janjetovic Snjezana, Klingler Felix, Knop Stefan, Röllig Christoph, Schwartz Stefan, Spriewald Bernd, Steffen Björn, Wethmar Klaus, Busch Hauke, Gökbuget Nicola, Baldus Claudia D, Bastian Lorenz, Brüggemann Monika
Abstract excerpt
ABSTRACT: Lenalidomide, a maintenance treatment in multiple myeloma first-line therapy, increases the risk of secondary malignancies, including B-cell precursor acute lymphoblastic leukemia (B-ALL). We present a comprehensive molecular characterization of 57 patients with lenalidomide-associated B-ALL (LenB-ALL), revealing 3 mutational subgroups: (1) TP53mt (30%); (2) IDH2mt (p.R140Q) (23%); and (3) other,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.